Skip to content

Altimmune ALT Free cash flow yield

Free cash flow yield at other companies

Eli Lilly logo
Eli LillyLLY
1.4%+0.9pp
Merck & Co. logo
Merck & Co.MRK
4.7%-2.8pp
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-4.9%-1.3pp
Wave Life Sciences logo
Wave Life SciencesWVE
-13.6%-0.9pp
Delcath Systems logo
Delcath SystemsDCTH
6%+4.8pp
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-18.3%-6.3pp

Other financials

Income statement

See full
Revenue$26.0K+420%
Operating income-$24.2M-11.1%
Net income-$22.6M-15.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$97.6M+98.7%
Total debt$34.8M+14,092%
Total equity$284.0M+99.8%
Total assets$335.6M+113%

Cash flow

See full
Operating cash flow-$20.9M-24.4%
CapEx$21.0K
Free cash flow-$21.0M

Valuation

See full
Market cap$558.14M-2.1%
Enterprise value$495.27M-5.0%
P/S13,613.2×-24,380×

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp
FCF margin-17,806.8%-110,030pp

Returns & leverage

See full
Return on equity-42.7%-8.7pp
Debt / equity0.1×+0.1×
Current ratio29.6×+13.7×

Where this comes from

Calculated from Altimmune’s reported figures.

Based on trailing twelve months.

The official record: Altimmune’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Altimmune's free cash flow yield?
Altimmune (ALT) reported free cash flow yield of -12.5% in Q4 2023.
How has Altimmune's free cash flow yield changed year-over-year?
Altimmune's free cash flow yield decreased by 61.8% year-over-year, from -7.8% to -12.5%.
What is the long-term trend for Altimmune's free cash flow yield?
Over 3 years (2020 to 2023), Altimmune's free cash flow yield has grown at a 17.7% compound annual growth rate (CAGR), from -7.7% to -12.5%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.